Arcus Biosciences, Inc. (RCUS)

Market Cap	1.41B
Revenue (ttm)	263.00M
Net Income (ttm)	-270.00M
Shares Out	91.51M
EPS (ttm)	-3.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122,783
Open	15.56
Previous Close	15.50
Day's Range	15.38 - 15.80
52-Week Range	13.52 - 20.31
Beta	0.85
Analysts	Buy
Price Target	34.50 (+123.81%)
Earnings Date	Nov 6, 2024

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclust...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 15, 2018
• Employees: 577
• Stock Exchange: NYSE
• Ticker Symbol: RCUS
• Website: https://www.arcusbio.com

Financial Performance

In 2023, Arcus Biosciences's revenue was $117.00 million, an increase of 4.46% compared to the previous year's $112.00 million. Losses were -$307.00 million, 15.0% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is $34.5, which is an increase of 123.81% from the latest price.

Price Target

$34.5

(123.81% upside)

Analyst Consensus: Buy